BioSpecifics Technologies Corp. is a profitable, biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Europe and Australia.

In addition to Dupuytren's contracture and Peyronie's disease, Endo is managing the research and development of XIAFLEX® for their six licensed clinical-stage indications, which include adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis and human and canine lipomas. Endio is conducting a commercial review of these indications. BioSpecifics is currently managing the development of XIAFLEX® for uterine fibroids and initiated a Phase 1 clinical trial in the second quarter of 2017 following promising preclinical data from a collaborative study with Duke Medicine. Data is expected in 2018. BioSpecifics also initiates the development of XIAFLEX® in new potential indications. Endo has the right to opt in to new indications.